-O-Mo位点激活纳米酶用于双酶/上转化协同催化抗癌疗法
Qiang Wang1, Shuang Liu1,2, Chunsheng Li1
1Key Laboratory of Forest Plant Ecology, Ministry of Education, College of Chemistry, Chemical Engineering and Resource Utilization, Northeast Forestry University, Harbin, 150040, P.R. China.
Angewandte Chemie (International ed. in English)
|September 17, 2025
概括
新的双原子纳米酶克服了单原子纳米酶的局限性,用于增强癌症治疗. 这些先进的纳米酶为协同治疗癌症提供了改善的催化活性和双模成像.
科学领域:
- 纳米技术和材料科学 材料科学
- 生物医学工程 生物医学工程
- 癌症治疗 癌症治疗
背景情况:
- 单原子纳米酶 (SAzymes) 对癌症治疗具有前景,但面临着低活性位密度和有限的中间吸附/脱附的挑战.
- 开发具有增强催化效率和成像能力的纳米酶对于有效的癌症治疗术至关重要.
研究的目的:
- 开发基于的新型Fe/Mo双原子半导体纳米酶 (FeMoDA),封装在化纳米粒子 (LPs) 中,并用氨酸 (HA) 进行表面修饰,用于协同催化疗法 (ET/UCT).
- 用第二次近红外 (NIR-II) 和磁共振 (MR) 成像来指导协同疗法.
- 研究开发的纳米酶的增强的催化性能和瘤响应性降解.
主要方法:
- 在LPs (HA/FeMoDA-LPs) 中封装的HA修饰的Fe/Mo双原子纳米酶的制造.
- 密度函数理论 (DFT) 计算以了解电子结构和催化机制.
- 在体外评估过氧化酶样 (POD) 活性,内细胞和微环境反应.
- 在NIR-II照射和瘤响应性降解下,研究上转触发的催化活性.
主要成果:
- DFT的计算证实了Fe-O-Mo协调优化了中间吸附/脱附,并增强了双酶活性.
- 与单原子对应物相比,HA/FeMoDA-LPs表现出优越的POD类催化性能,Km为11.54mM,Vmax为1.14 × 10-7 M·s-1 .
- HA修饰显著增强了内细胞分裂 (∼5.67倍) 和微环境酸化,促进了ET.
- 通过上转换触发的电子/孔对和POD类活动实现了协同ET/UCT,产生反应性氧物种 (ROS).
- 瘤微环境因素 (H+和谷氨) 诱导纳米酶降解,增强NIR-II和MR成像信号.
结论:
- 与传统的SAzymes相比,HA/FeMoDA-LPs代表了癌症治疗药物的优越协同作用和瘤响应平台.
- 开发的纳米酶为有效的癌症治疗提供了增强的催化性能和双模成像能力.
- 这项工作为设计基于纳米酶的先进疗法提供了一个有前途的策略.
相关概念视频
02:47Ribozymes
3.4K
3.4K
02:47Ribozymes
13.3K
The term ribozyme is used for RNA that can act as an enzyme. Ribozymes are mainly found in selected viruses, bacteria, plant organelles, and lower eukaryotes. Ribozymes were first discovered in 1982 when Tom Cech’s laboratory observed Group I introns acting as enzymes. This was shortly followed by the discovery of another ribozyme, Ribonulcease P, by Sid Altman’s laboratory. Both Cech and Altman received the Nobel Prize in chemistry in 1989 for their work on ribozymes.
Ribozymes can...
Ribozymes can...
13.3K
01:07Catalytically Perfect Enzymes
4.9K
The theory of catalytically perfect enzymes was first proposed by W.J. Albery and J. R. Knowles in 1976. These enzymes catalyze biochemical reactions at high-speed. Their catalytic efficiency values range from 108-109 M-1s-1. These enzymes are also called 'diffusion-controlled' as the only rate-limiting step in the catalysis is that of the substrate diffusion into the active site. Examples include triose phosphate isomerase, fumarase, and superoxide dismutase.
Most enzymes...
Most enzymes...
4.9K
02:57Targeted Cancer Therapies
8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.6K
01:46Electron Transport Chain: Complex I and II
18.5K
The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...
ROS generation is regulated and maintained at moderate levels necessary...
18.5K
01:27Transducer Mechanism: Enzyme-Linked Receptors
3.9K
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
3.9K